================================================================================

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                           ---------------------------

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                                  June 18, 1998
                Date of Report (Date of earliest event reported)

                             AVAX TECHNOLOGIES, INC.
             (Exact name of Registrant as specified in its charter)

          Delaware                      000-29222               13-3575874
(State or other jurisdiction     (Commission File Number)     (IRS Employer
     of incorporation)                                    Identification Number)

                                4520 Main Street
                                    Suite 930
                              Kansas City, MO 64111
                    (Address of principal executive offices)

                                 (816) 960-1333
              (Registrant's telephone number, including area code)

                                Page 1 of 5 Pages
                         Exhibit Index Appears at Page 3

================================================================================
<PAGE>

Item 5. Other Events

            AVAX Technologies, Inc. (the "Company"), announced on Thursday, June
18, 1998 that a United States patent was issued covering anticancer technology
it licensed from Rutgers University for exclusive development and worldwide
marketing. The patent, U.S. No. 5,752,142 grants claims to novel compounds which
inhibit activity of topoisomerase I, a natural enzyme needed to support
malignant tumor growth.

            Reference is made to the Company's related press release attached
hereto as Exhibit 99.13 and incorporated by reference herein (including, without
limitation, the information set forth in the cautionary statement contained in
the final paragraph of the press release).

Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits

      (c) Exhibits:

          99.13 Press Release dated June 18, 1998.

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                         AVAX TECHNOLOGIES, INC.

Date:  June 18, 1998


                                         By: /s/ Jeffrey M. Jonas
                                            ------------------------------------
                                            Name: Jeffrey M. Jonas, M.D.
                                            Title: President and Chief Executive
                                                   Officer


                                       2
<PAGE>

                                  Exhibit Index

  Exhibit Number                            Description
  --------------                            -----------

     99.13                       Press Release dated June 18, 1998.


                                        3
[{"type": "8-K", "sequence": "1", "description": "FORM 8-K", "secsgml_size_bytes": 3323}]
{"company-data": {"conformed-name": "AVAX TECHNOLOGIES INC", "cik": "0001015441", "assigned-sic": "2836", "irs-number": "133575874", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-29222", "film-number": "98650358"}, "business-address": {"street1": "4520 MAIN ST", "street2": "STE 930", "city": "KANSAS CITY", "state": "MO", "zip": "64112", "phone": "8169601333"}, "mail-address": {"street1": "4520 MAIN STREET SUITE 930", "city": "KANSAS CITY", "state": "MO", "zip": "64112"}}
================================================================================

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                           ---------------------------

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                                  June 18, 1998
                Date of Report (Date of earliest event reported)

                             AVAX TECHNOLOGIES, INC.
             (Exact name of Registrant as specified in its charter)

          Delaware                      000-29222               13-3575874
(State or other jurisdiction     (Commission File Number)     (IRS Employer
     of incorporation)                                    Identification Number)

                                4520 Main Street
                                    Suite 930
                              Kansas City, MO 64111
                    (Address of principal executive offices)

                                 (816) 960-1333
              (Registrant's telephone number, including area code)

                                Page 1 of 5 Pages
                         Exhibit Index Appears at Page 3

================================================================================
Item 5. Other Events

            AVAX Technologies, Inc. (the "Company"), announced on Thursday, June
18, 1998 that a United States patent was issued covering anticancer technology
it licensed from Rutgers University for exclusive development and worldwide
marketing. The patent, U.S. No. 5,752,142 grants claims to novel compounds which
inhibit activity of topoisomerase I, a natural enzyme needed to support
malignant tumor growth.

            Reference is made to the Company's related press release attached
hereto as Exhibit 99.13 and incorporated by reference herein (including, without
limitation, the information set forth in the cautionary statement contained in
the final paragraph of the press release).

Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits

      (c) Exhibits:

          99.13 Press Release dated June 18, 1998.

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                         AVAX TECHNOLOGIES, INC.

Date:  June 18, 1998

                                         By: /s/ Jeffrey M. Jonas
                                            ------------------------------------
                                            Name: Jeffrey M. Jonas, M.D.
                                            Title: President and Chief Executive
                                                   Officer

                                       2
Exhibit Index

  Exhibit Number                            Description
  --------------                            -----------

     99.13                       Press Release dated June 18, 1998.

                                        3